---
title: "Humacyte, Inc. (HUMA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HUMA.US.md"
symbol: "HUMA.US"
name: "Humacyte, Inc."
industry: "Biotechnology"
datetime: "2026-06-13T16:50:27.901Z"
locales:
  - [en](https://longbridge.com/en/quote/HUMA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HUMA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HUMA.US.md)
---

# Humacyte, Inc. (HUMA.US)

## Company Overview

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.humacyte.com](https://www.humacyte.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:13.000Z

**Overall: D (0.67)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 254 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 289.94% |  |
| Net Profit YoY | -18.96% |  |
| P/B Ratio | 20.15 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 234230158.94 |  |
| Revenue | 2016000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -399.51% | E |
| Profit Margin | -4840.82% | E |
| Gross Margin | -4122.22% | E |
| Revenue YoY | 289.94% | A |
| Net Profit YoY | -18.96% | D |
| Total Assets YoY | -31.99% | E |
| Net Assets YoY | -67.75% | E |
| Cash Flow Margin | 106.65% | C |
| OCF YoY | 289.94% | A |
| Turnover | 0.01 | E |
| Gearing Ratio | 89.49% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Humacyte, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "289.94%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.96%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "20.15",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "234230158.94",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2016000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-399.51%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-4840.82%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-4122.22%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "289.94%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.96%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-31.99%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-67.75%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "106.65%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "289.94%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "89.49%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.46 | 274/390 | - | - | - |
| PB | 20.15 | 423/390 | 67.48 | 50.34 | 10.63 |
| PS (TTM) | 116.19 | 260/390 | 370.88 | 149.88 | 118.52 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-11T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 60% |
| Overweight | 1 | 20% |
| Hold | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.05 |
| Highest Target | 3.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HUMA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HUMA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HUMA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HUMA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**